These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29084148)

  • 1. Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations.
    Alimohammadi M; Punga AR
    Toxins (Basel); 2017 Oct; 9(11):. PubMed ID: 29084148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: a double-blind, placebo-controlled, randomized study.
    Alimohammadi M; Andersson M; Punga AR
    Acta Derm Venereol; 2014 Jan; 94(1):32-7. PubMed ID: 23975053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes.
    Glogau RG
    Clin J Pain; 2002; 18(6 Suppl):S191-7. PubMed ID: 12569968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients.
    Blitzer A; Binder WJ; Aviv JE; Keen MS; Brin MF
    Arch Otolaryngol Head Neck Surg; 1997 Apr; 123(4):389-92. PubMed ID: 9109785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA; Fallico N; Mazzocchi M; Scuderi N
    Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Focal dystonias and facial hemispasm: treatment with botulinum A toxin].
    Astarloa R; Morales B; Sánchez V; Peñafiel N; Rábano J; Oliván J; García de Yébenes J
    Arch Neurobiol (Madr); 1991; 54 Suppl 3():44-51. PubMed ID: 1810208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Focal dystonias and facial hemispasm: treatment with botulinum A toxin].
    Astarloa R; Morales B; Sánchez V; Peñafiel N; Rábano J; Oliván J; García de Yébenes J
    Arch Neurobiol (Madr); 1991; 54(5):210-7. PubMed ID: 1804035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of botulinum A toxin to ameliorate facial kinetic frown lines.
    Foster JA; Barnhorst D; Papay F; Oh PM; Wulc AE
    Ophthalmology; 1996 Apr; 103(4):618-22. PubMed ID: 8618761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum Toxin Type-A (BoNT-A) Injections of the Corrugator Muscles for Aesthetics and Depression?
    Brennan C
    Plast Surg Nurs; 2016; 36(4):167-169. PubMed ID: 27922559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion, spread, and migration of botulinum toxin.
    Ramirez-Castaneda J; Jankovic J; Comella C; Dashtipour K; Fernandez HH; Mari Z
    Mov Disord; 2013 Nov; 28(13):1775-83. PubMed ID: 23868503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hemifacial spasm with botulinum toxin.
    Yoshimura DM; Aminoff MJ; Tami TA; Scott AB
    Muscle Nerve; 1992 Sep; 15(9):1045-9. PubMed ID: 1518513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the botulinum neurotoxins.
    Carruthers A; Carruthers J
    Skin Therapy Lett; 2001 Dec; 6(13):1-2. PubMed ID: 11813096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sonoanatomy of injecting botulinum neurotoxin into the facial muscles.
    Kim SB; Hu H; Lee HJ; Yi KH
    Surg Radiol Anat; 2024 Aug; 46(8):1237-1252. PubMed ID: 38942935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment.
    Xiao L; Pan Y; Zhang X; Hu Y; Cai L; Nie Z; Pan L; Li B; He Y; Jin L
    Neurol Sci; 2016 Nov; 37(11):1807-1813. PubMed ID: 27431279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis.
    Yamauchi PS; Lowe NJ
    Clin Dermatol; 2004; 22(1):34-9. PubMed ID: 15158543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum Toxin Type A to Improve Facial Symmetry in Facial Palsy: A Practical Guideline and Clinical Experience.
    de Sanctis Pecora C; Shitara D
    Toxins (Basel); 2021 Feb; 13(2):. PubMed ID: 33670477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety.
    Wollmer MA; Makunts T; Krüger THC; Abagyan R
    Sci Rep; 2021 Dec; 11(1):24173. PubMed ID: 34934096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aesthetic use of BoNT: Options and outcomes.
    Gendler E; Nagler A
    Toxicon; 2015 Dec; 107(Pt A):120-8. PubMed ID: 26368007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of botulinum toxin injections in dystonia.
    Ramirez-Castaneda J; Jankovic J
    Toxins (Basel); 2013 Feb; 5(2):249-66. PubMed ID: 23381141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.